IXICO (LSE:IXI) EV-to-EBIT

: -0.44 (As of Today)

View and export this data going back to 1996. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, IXICO's Enterprise Value is £0.59 Mil. IXICO's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was £-1.33 Mil. Therefore, IXICO's EV-to-EBIT for today is -0.44.

The historical rank and industry rank for IXICO's EV-to-EBIT or its related term are showing as below:

LSE:IXI' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.2 Med: 0.23 Max: 98.42
Current: -0.44

During the past 13 years, the highest EV-to-EBIT of IXICO was 98.42. The lowest was -16.20. And the median was 0.23.

LSE:IXI's EV-to-EBIT is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 8.685 vs LSE:IXI: -0.44

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. IXICO's Enterprise Value for the quarter that ended in Sep. 2023 was £5.54 Mil. IXICO's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was £-1.33 Mil. IXICO's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -24.03%.

IXICO EV-to-EBIT Historical Data

The historical data trend for IXICO's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Annual Data

Trend

Sep13

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EV-to-EBIT

45.51

43.32

28.98

11.85

-4.16

IXICO Semi-Annual Data
	Sep13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EV-to-EBIT																28.98	-	11.85	-	-4.16

Competitive Comparison

For the Biotechnology subindustry, IXICO's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IXICO EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, IXICO's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where IXICO's EV-to-EBIT falls into.

IXICO EV-to-EBIT Calculation

IXICO's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.587	/	-1.332
	=	-0.44

IXICO's current Enterprise Value is £0.59 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. IXICO's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was £-1.33 Mil.

IXICO (LSE:IXI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

IXICO's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-1.332	/	5.542766
	=	-24.03 %

IXICO's Enterprise Value for the quarter that ended in Sep. 2023 was £5.54 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. IXICO's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was £-1.33 Mil.

IXICO EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of IXICO's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

IXICO (LSE:IXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

PHYOF:USA

Address

15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website

https://www.ixico.com

IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines